Select Page

About Us

We believe in this technology and its ability to have a truly positive impact in Oncology.
OncoSil™ For Healthcare Professionals

Our Approvals

We operate from 2 locations globally with access to 11 global markets via direct sales and distributors and operates facilities in Germany.

Global Headquaters

Global Headquarters
OncoSil Medical Ltd.
Suite 503, Level 5, 15 Blue Street,
North Sydney, NSW 2060

European Office

OncoSil Medical Europe GmbH
Kurfuerstendamm 195/3rd Fl.
10707 Berlin

Learn more about our achievements and the people behind them.

Our People
Our History
References:
1. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine based chemotherapy.
2. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.
3. PanCO ClinicalTrials.gov Identifier: NCT03003078
4. OncoPaC-1 ClinicalTrials.gov Identifier: NCT03076216
5. PanCO Publication